Experience with type I interferon inhibitor in systemic lupus erythematosus

Abstract

The article describes a clinical case of systemic lupus erythematosus (SLE) resistant to traditional treatment regimens and the first successful experience with the type I interferon inhibitor – anifrolumab, as part of an early access program in the Russian Federation. High efficacy and safety of the drug in the treatment of SLE with active lesions of the skin, mucous membranes and joints were noted.

Keywords

• systemic lupus erythematosus
• discoid lupus erythematosus
• type i interferon inhibitor
• anifrolumab
• clinical case